TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04545073

Intervention type: DEVICE
Intervention: PanOptix
Description: Trifocal IOL with ORA in post refractive patients
Study: NCT04140409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin
Description: All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.
Study: NCT00461734

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RV lead placement site
Description: Patients randomised to RV apical or high septal lead placement site

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RV lead placement site
Description: Patients randomised to RV apical or high septal lead placement site
Study: NCT02121210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarilumab SAR153191 (REGN88)
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
Study: NCT04405336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tab block
Description: injection of tab block to women who are doing cs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCA
Description: giving women PCA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: women who will not receive tab block or PCA
Description: no tab block or PCA will be given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: women who will not receive tab block or PCA
Description: no tab block or PCA will be given
Study: NCT03043196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP plus Rosuvastatin gel
Description: SRP followed by Rosuvastatin placement into intrabony defect

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SRP plus placebo gel
Description: SRP followed by placebo gel placement into intrabony defect
Study: NCT02590458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short Breast MRI (SBMRI)
Description: One day after routine MRI, short breast MRI (SBMRI) with contrast performed. Scan will take about 10 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan. It should take about 10 minutes to complete the questionnaire.
Study: NCT03744832

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Alere i™ Strep A assay
Description: Point of care (POC) molecular-based, nucleic acid amplification test (NAAT). This isothermal molecular assay is CLIA waived (Clinical Laboratory Improvement Amendments) and Health Canada licensed for POC use, and is anticipated to have approval for use without need for back up culture testing.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Throat culture
Description: Standard bacterial throat culture.
Study: NCT01226329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Right Question Project - Mental Health (RQP-MH)
Description: The RQP-MH trainings each take approximately 45 minutes to complete and are delivered approximately three weeks apart. The manualized intervention uses a Question Formulation Technique (QFT) and a Framework for Active Decision-Making (FADM). The QFT consists of asking patients to generate and revise questions to obtain more informative answers from their providers. The FADM teaches participants to identify questions that will help them consider their role in a decision, the process of decision-making, and the reasons behind a decision. All intervention sessions will be taught by a bachelors-level Care Manager.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlet
Description: Participants in this group receive a handout called Managing Your Mental Health (available in Spanish and English) that provides tips on how to manage mental health through the proper maintenance of physical health and stress.
Study: NCT02776566

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Self-Monitoring vs Anticoagulation Clinic
Description: Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages.~Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Self-Monitoring vs Anticoagulation Clinic
Description: Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages.~Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic.
Study: NCT00402831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProQuad®
Description: Each dose (0.5 mL) contains live attenuated versions of measles virus Enders' Edmonston strain, mumps virus Jeryl Lynn™ (Level B) strain, rubella virus Wistar RA 27/3 strain, and varicella virus Oka/Merck strain.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ProQuad®
Description: Each dose (0.5 mL) contains live attenuated versions of measles virus Enders' Edmonston strain, mumps virus Jeryl Lynn™ (Level B) strain, rubella virus Wistar RA 27/3 strain, and varicella virus Oka/Merck strain.
Study: NCT02483884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]RM2
Description: \[68Ga\]RM2 is a novel 68Ga labeled, radiopharmaceutical agent for PET imaging. It is administered intravenously as a single dose of 140 MBq (corresponding to ≤ 40 μg mass dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]RM2
Description: \[68Ga\]RM2 is a novel 68Ga labeled, radiopharmaceutical agent for PET imaging. It is administered intravenously as a single dose of 140 MBq (corresponding to ≤ 40 μg mass dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]RM2
Description: \[68Ga\]RM2 is a novel 68Ga labeled, radiopharmaceutical agent for PET imaging. It is administered intravenously as a single dose of 140 MBq (corresponding to ≤ 40 μg mass dose)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Patients received \[68Ga\]RM2 undergo PET/CT 60 min p.i. for at least 20 min

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Patients received \[68Ga\]RM2 undergo PET/CT 60 min p.i. for at least 20 min

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Patients received \[68Ga\]RM2 undergo PET/CT 60 min p.i. for at least 20 min
Study: NCT04773028

Intervention type: OTHER
Intervention: matrix metalloproteinase enzymes 2 and 9
Description: concentration of matrix metalloproteinase 2 and 9 enzymes

Intervention type: OTHER
Intervention: matrix metalloproteinase enzymes 2 and 9
Description: concentration of matrix metalloproteinase 2 and 9 enzymes
Study: NCT01833676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Study: NCT01577797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: Messages sent at random intervals 4 times per day during weeks 1 and 3. Subjects can also request messages if they are craving methamphetamine

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Text messages
Description: Messages sent at random intervals 4 times per day during weeks 1 and 3. Subjects can also request messages if they are craving methamphetamine
Study: NCT04145063

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no stent
Description: following uretroscopy, no stent will be placed
Study: NCT02909062

Intervention type: DEVICE
Intervention: Electronic Activity Monitoring (EAM)
Description: All registered patients will receive a wearable EAM device that will measure their physical activity. Patients will wear this device around their wrist for the designated period of assessment. The EAM device has the potential to measure active minutes, number of steps, distance walked and number of floors climbed. For the purpose of this study the EAM data captured will focus on daily step count.

Intervention type: BEHAVIORAL
Intervention: Daily Questionnaire
Description: Participants will be asked to complete this self-administered, paper-based questionnaire each day that they are expected to wear the EAM device. The questionnaire was designed specifically for the purpose of this study. It consists of 5 items that ask about the patient's perceived level of physical activity and fatigue in each 24 hour period that they have worn the EAM device. The daily questionnaires will be optional; however each participant will be encouraged to complete them.
Study: NCT02644018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imidazolyl ethanamide pentandioic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02530437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taladegib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taladegib
Description: Given PO
Study: NCT02139540

Intervention type: DRUG
Group type: OTHER
Intervention: Nitrous Oxide
Description: Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or placebo (50% nitrogen \[inert\]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart.

Intervention type: DRUG
Group type: OTHER
Intervention: Nitrous Oxide
Description: Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or placebo (50% nitrogen \[inert\]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 50% nitrogen \[inert\]/50% oxygen - otherwise completely identical administration and setup

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 50% nitrogen \[inert\]/50% oxygen - otherwise completely identical administration and setup
Study: NCT01313754

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vicryl Suture
Description: Vicryl suture material will be placed on the patients left sided incision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dermabond
Description: Dermabond skin glue will be placed on the patients left sided incision.
Study: NCT03307421

Intervention type: OTHER
Group type: OTHER
Intervention: debriefing without instructor
Description: The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.~The sequence of scenarios for each binomial will also be determined by randomization.

Intervention type: OTHER
Group type: OTHER
Intervention: debriefing with instructor
Description: The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.
Study: NCT04003909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided Erector spinae plane block
Description: The patients will be in lateral position. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. Local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle will be inserted inplane to the ultrasound beam in a cranial-to-caudal direction until contact made with the L4 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total volume of 20ml bupivicaine 0.25% and 20 ml xylocaine 1% will be injected into the ESP on the affected side.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subarachonoid block
Description: Local anesthesia 2ml of lidocaine 2% will be applied intradermally to the needle entrance point. A 22-G block needle will be inserted, free cerebrospinal fluid flow will be observed and 20mg of hyperbaric bupivacaine 0.5% and 10μg of fentanyl will be injected for 30 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subarachonoid block
Description: Local anesthesia 2ml of lidocaine 2% will be applied intradermally to the needle entrance point. A 22-G block needle will be inserted, free cerebrospinal fluid flow will be observed and 20mg of hyperbaric bupivacaine 0.5% and 10μg of fentanyl will be injected for 30 seconds.
Study: NCT01378208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting - the effect on glucose metabolism, body composition and cognitive function
Description: Each of the 10 subjects must through a period of monitoring (four weeks) before the study period (four weeks). Before, during, and after both the monitoring period and the study period, the subjects will undergo tests at Rigshospitalet.~DAY 1: Inclusion and exclusion of subjects DAY 1 to DAY 28: Monitoring period (usual lifestyle)~* 28 days of dietary monitoring~* 28 days measurement by pedometer DAY 1, DAY 28 \& DAY 56: Test 1~* Oral glucose tolerance test with stable isotopes~* Fat and muscle biopsies DAY 2, DAY 29 \& DAY 57: Test 2~* DXA scanning~* Resting Metabolic Rate Measurement~* VO2max test on bicycle~* Cognitive testing~* MRI of the brain and abdomen DAY 9, DAY 19, DAY 38 \& DAY 48: Test 3~* Actiheart for 3 days~* 72-hour blood glucose monitoring with CGMS System DAY 29 to DAY 57: INTERVENTION~* Fasting from 7am - 9pm~* 28 days of dietary monitoring~* 28 days measurement by pedometer
Study: NCT01646437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polycap
Description: Polycap (thiazide 25mg, atenolol 100mg, ramipril 10mg, simvastatin 40mg) taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 75 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 60,000 IU monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching Placebo
Study: NCT03180710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone® Combo 75/25 at 0.6 U/kg
Description: Injection of BioChaperone® Combo 75/25 at 0.6 U/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone® Combo 75/25 at 0.8 U/kg
Description: Injection of BioChaperone® Combo 75/25 at 0.8 U/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone® Combo 75/25 at 1.0 U/kg
Description: Injection of BioChaperone® Combo 75/25 at 1.0 U/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog® Mix25 at 0.8 U/kg
Description: Injection of Humalog® Mix25 at 0.8 U/kg
Study: NCT03156075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and exercise program
Description: Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn.
Study: NCT01004939

Intervention type: DRUG
Intervention: fondaparinux
Description: fondaparinux
Study: NCT03560908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 70mg twice a day will be administered orally for 2 weeks along with re-induction chemotherapy from day 1 of chemotherapy. Recommended re-induction regimens include (1)FLAG: Fludarabine 30mg/m2/d,d1-5;cytarabine 1g-2g/m2/d,d1-5;±G-CSF;(2)IA/DA:idarubicin 8-12mg/m2/d,d1-3 or daunorubicin 45-60mg/m2/d，d1-3;cytarabine 100-200mg/m2/d，d1-7;(3)CAG:Aclarubicin 20mg/d,d1-4；cytarabine 15mg/m2/Q12h,d1-14; ±G-CSF.The chemotherapy regimen is not limited to recommended regimens. Patients will be recommended to receive allogeneic hematopoietic stem cell transplantation (HSCT) once complete remission is achieved. Otherwise, they will continue the consolidation chemotherapy.
Study: NCT02084823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: cancer stem cell vaccine
Study: NCT01896063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Study: NCT04421417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture + Standard Arthroscopic Rotator Cuff Repair
Description: drilling of rotator cuff footprint area on humerus and standard arthroscopic rotator cuff repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Arthroscopic Rotator Cuff Repair
Description: Standard Arthroscopic Rotator Cuff Repair
Study: NCT04700865

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AF screening
Description: Continous ECG monitoring for minimum 3 days
Study: NCT01387269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anamorelin HCl
Description: Anamorelin HCl will be orally administered daily at least one hour before meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour before meal
Study: NCT01348841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic referral to MDWCT and comprehensive primary care
Description: Systematic referral to, and follow up, by Multi-Disciplinary Wound Care Teams (MDWCTs), co-ordinated by the Case Manager (CM), will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4.
Study: NCT03684408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFID Localization
Description: The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wire Localization
Description: The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
Study: NCT00989625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: This is a pharmacokinetic study (Treximet)
Description: This is a pharmacokinetic study to collect PK samples from subject after single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: This is a pharmacokinetic study (Treximet)
Description: This is a pharmacokinetic study to collect PK samples from subject after single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: This is a pharmacokinetic study (Treximet)
Description: This is a pharmacokinetic study to collect PK samples from subject after single dose.
Study: NCT03329755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dedicated and coordinated e-follow-up during the treatment period
Description: * Completion of questionnaires using an electronic tool~* Telephone follow-up between the nurse and the patient~* Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard follow-up during the treatment period
Description: - Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)
Study: NCT03684408

Intervention type: DEVICE
Group type: OTHER
Intervention: RFID and Wire Localization
Description: Both RFID and the standard of care wire localization will be performed for physician training.
Study: NCT00416273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered as 1.6 mg/m2 per body surface area on the days 1, 8, 15, 22 for the duration of 4 therapy cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Participants in the observation group will be observed and will not receive any consolidation therapy.